Romipeptides A and B, two new romidepsin derivatives isolated from Chromobacterium violaceum No.968 and their antitumor activities in vitro.
10.1016/S1875-5364(19)30018-4
- Author:
Lei XIONG
1
;
Chang-Fa CHEN
1
;
Tao-Ling MIN
1
;
Hai-Feng HU
2
,
3
Author Information
1. State Key Lab of New Drug & Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200000, China.
2. State Key Lab of New Drug & Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 200000, China. Electronic address: haifenghu88@
3. com.
- Publication Type:Journal Article
- Keywords:
Chromobacterium violaceum;
Cytotoxicity;
Romidepsin derivatives
- MeSH:
Antineoplastic Agents;
chemistry;
pharmacology;
Cell Line, Tumor;
Cell Proliferation;
drug effects;
Cell Survival;
drug effects;
Chemistry Techniques, Analytical;
Chromobacterium;
metabolism;
Depsipeptides;
chemistry;
pharmacology;
Dipeptides;
chemistry;
Drug Screening Assays, Antitumor;
Fermentation;
Humans;
Molecular Structure;
Peptides, Cyclic;
chemistry
- From:
Chinese Journal of Natural Medicines (English Ed.)
2019;17(2):155-160
- CountryChina
- Language:English
-
Abstract:
Romipeptides A and B (1 and 2), two new romidepsin derivatives, and three known compounds, chromopeptide A (3), romidepsin (4) and valine-leucine dipeptide (5) were isolated from the fermentation broth of Chromobacterium violaceum No. 968. Their structures were elucidated by interpretation of their UV, HR-ESI-MS and NMR spectra. The absolute configuration of compound 1 and 2 were established by single crystal X-ray diffraction analysis. Compounds 1-5 were evaluated for their anti-proliferative activities against three human cancer cell lines, SW620, HL60, and A549. The results showed most of these compounds exhibited antitumor activities in vitro, in which compound 2 displayed potent cytotoxicity to SW620, HL60 and A549 cell lines, with IC of 12.5, 6.7 and 5.7 nmol·L, respectively.
